Study details
Enrolling now
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Philip Kern
NCT IDNCT05051436ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
96
Study length
about 4.1 years
Ages
35–65
Locations
1 site in KY
What this study is about
This trial is testing whether mirabegron, tadalafil, or both improve glucose control in people with prediabetes. Participants will take either mirabegron, tadalafil, a combination of the two, or a placebo for 14 weeks and their blood sugar levels will be monitored.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Mirabegron 50 MG
- 2.Take Placebo
- 3.Take Tadalafil 10 MG
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
mirabegron, tadalafil
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Hemoglobin A1C
Body systems
Endocrinology